BACKGROUND AND PURPOSE: We and others have demonstrated previously an improved detection rate for bladder cancer recurrences with narrow-band imaging (NBI) flexible cystoscopy when compared with conventional white-light imaging (WLI) flexible cystoscopy. We investigated whether a "new user" of NBI flexible cystoscopy, previously unfamiliar with this technique, could reproduce these results. PATIENTS AND METHODS: The same protocol from our previous study was used by a new user (ZHS) for this second study at The Queen Elizabeth Hospital, Birmingham, United Kingdom. NBI flexible cystoscopy was performed on 23 patients with known recurrences of urothelial cancer (UC) of the bladder after initial conventional WLI flexible cystoscopy with the same switchable Olympus Lucera sequential red/green/blue instrument. RESULTS: NBI detected 15 additional UCs in 8 of the 23 (35%) patients: Six of these patients had one additional UC, one had four additional UCs, and one had five additional UCs when compared with WLI, with a mean of 0.65 additional UCs per patient (standard deviation 1.30; Wilcoxon P = 0.01). When this second series is compared with our first published series, there is no statistical evidence that the excess number of UCs detected by NBI is different (Wilcoxon [unpaired] signed-rank test P = 0.74), which suggests that there is no difference between a new user and an experienced user in the application of NBI. CONCLUSIONS: We and others continue to demonstrate a significantly improved detection rate of bladder UCs with NBI cystoscopy when compared with conventional WLI cystoscopy, even for new users previously unfamiliar with this technology.
BACKGROUND AND PURPOSE: We and others have demonstrated previously an improved detection rate for bladder cancer recurrences with narrow-band imaging (NBI) flexible cystoscopy when compared with conventional white-light imaging (WLI) flexible cystoscopy. We investigated whether a "new user" of NBI flexible cystoscopy, previously unfamiliar with this technique, could reproduce these results. PATIENTS AND METHODS: The same protocol from our previous study was used by a new user (ZHS) for this second study at The Queen Elizabeth Hospital, Birmingham, United Kingdom. NBI flexible cystoscopy was performed on 23 patients with known recurrences of urothelial cancer (UC) of the bladder after initial conventional WLI flexible cystoscopy with the same switchable Olympus Lucera sequential red/green/blue instrument. RESULTS: NBI detected 15 additional UCs in 8 of the 23 (35%) patients: Six of these patients had one additional UC, one had four additional UCs, and one had five additional UCs when compared with WLI, with a mean of 0.65 additional UCs per patient (standard deviation 1.30; Wilcoxon P = 0.01). When this second series is compared with our first published series, there is no statistical evidence that the excess number of UCs detected by NBI is different (Wilcoxon [unpaired] signed-rank test P = 0.74), which suggests that there is no difference between a new user and an experienced user in the application of NBI. CONCLUSIONS: We and others continue to demonstrate a significantly improved detection rate of bladder UCs with NBI cystoscopy when compared with conventional WLI cystoscopy, even for new users previously unfamiliar with this technology.